JPRN-UMIN000036835尚未招募未知
DAA therapy and ADAMTS13/VWF for HCV - DAA therapy and ADAMTS13/VWF for HCV
ara Medical University0 个研究点目标入组 50 人开始时间: 2020年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)The impossible of oral intake 2)The pharmacokinetics is changed for patient's condition 3)The necessary medicine change the pharmacokinetics of rifaximin 4)The pregnancy and lactating 5)The allergy of rifaximin 6)The outcome evaluation is difficult for patient's condition 7)The execution plan of achievement is difficult
研究者
相似试验
尚未招募
不适用
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in VietnamHIV InfectionHepatitis C InfectionNCT05506475Institut Pasteur400
已完成
不适用
Interferon-free HCV eradication after curative treatment of hepatocellular carcinoma Gastroenterologist of Tokyo university Outsiders (GTO) Study GroupHCV related HCC patients after curative treatment of HCCJPRN-UMIN000022585Japanese Red Cross Medical Center56
已完成
不适用
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis CHepatitis CNCT02526641University of Aarhus16
终止
不适用
Re-treatment of HCV Following DAA FailureChronic Hepatitis CNCT03483987Sanjay Gandhi Postgraduate Institute of Medical Sciences18
已完成
不适用
Current Treatment of HCV Infection After HSCTHepatitis CNCT03014986European Society for Blood and Marrow Transplantation46